Skip to content
Review

Clinical and Molecular Outcomes of Dabrafenib/Trametinib-Based Combination Therapy in Acquired BRAF V600E-Mutant NSCLC Following Tyrosine Kinase Inhibitor Resistance: A Preliminary Single-Center Retrospective Study.

Oct 2026 · Combinatorial chemistry & high throughput screening · Vol 29 · 0 citations
Medicine

TL;DR

Dabrafenib/trametinib-based combination therapy may show clinical activity in selected patients with acquired BRAF V600E-mutant NSCLC after TKI resistance, however, the extremely small sample size, heterogeneous outcomes, and clinically significant toxicities preclude definitive conclusions regarding efficacy or safety.

Abstract

INTRODUCTION Acquired BRAF V600E is an uncommon resistance mechanism after tyrosine kinase inhibitor (TKI) therapy in oncogene-driven non-small cell lung cancer (NSCLC), and the clinical value of dabrafenib/trametinib-based combination therapy remains unclear. This preliminary single-center retrospective study aimed to describe the clinical, molecular, radiological, and safety outcomes of dabrafenib/trametinib-based combination therapy in patients with acquired BRAF V600E-mutant NSCLC after TKI resistance.

Methods

Patients with acquired BRAF V600E-mutant NSCLC after prior EGFR/ALK TKI therapy between December 2019 and September 2023 were retrospectively reviewed. Clinical characteristics, treatment outcomes, adverse events, radiological findings, and serial molecular profiles from plasma, tissue, or pleural effusion samples were collected.

Results

Three eligible patients were identified. The observed progression-free survival after dabrafenib/trametinib combination therapy was 2.2, 7.1, and 14.5 months. Toxicity was heterogeneous, including clinically significant pyrexia, treatment interruption, grade 2 hematologic toxicities, and rapid clinical deterioration in one patient. Among two patients with baseline brain metastases, intracranial lesions remained radiologically controlled during the available followup; however, this finding was descriptive and should not be interpreted as a reliable control rate. Serial molecular testing showed BRAF V600E disappearance after progression in selected cases, suggesting molecular heterogeneity.

Discussion

Acquired BRAF V600E mutation is a key secondary resistance mechanism after EGFR/ALK TKI therapy. Combining BRAF/MEK and EGFR/ALK inhibitors is a feasible strategy for these patients. However, the varied treatment outcomes and toxicities highlight the high clinical and molecular heterogeneity of this disease. Because of our extremely small sample size and retrospective design, larger prospective studies are needed to confirm these preliminary findings.

Conclusion

Dabrafenib/trametinib-based combination therapy may show clinical activity in selected patients with acquired BRAF V600E-mutant NSCLC after TKI resistance. However, the extremely small sample size, heterogeneous outcomes, and clinically significant toxicities preclude definitive conclusions regarding efficacy or safety.

View source

Similar papers

Oct 2026

Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights.

BACKGROUND Brain metastases (BM) are frequent in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) and remain challenging after prior EGFR tyrosine kinase inhibitor (TKI) therapy. This exploratory study evaluated high-dose fimmonertinib and explored subtype-specific spatial biology. METHODS iFORCE was a prospec...

M. You, Tong-Ji Xie, Li-Ge Wu et al. · 0 citations
Open access Sep 2026

Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.

Final analyses from this phase 2 study further supported substantial activity and prolonged OS with lorlatinib in treatment-naive and previously treated patients with ALK-positive advanced NSCLC, regardless of the biomarker subgroups.

T. Bauer, J. Martini, B. Besse et al. · 0 citations
Oct 2026

Clinical Outcomes and Prognostic Factors of ABCP Therapy in EGFR-mutated NSCLC in the Osimertinib Era

Background/Aim: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy has demonstrated efficacy in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) failure. However, real-world evidence in the osimertinib era remains limited. T...

Y. Taniguchi, Tsunehiro Tanaka, M. Tamiya et al. · 0 citations
Review Open access Oct 2026

Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.

PURPOSE MET amplification accounts for up to 30% of acquired resistance to EGFR-TKI, especially following third-generation EGFR-TKI treatment, yet precision-targeted therapeutic options remain limited. Early-phase studies demonstrated promising antitumor activity with the MET-TKI dalmelitinib combined with the third-ge...

Zi-Ming Li, Xiao-Rong Dong, Yan Yu et al. · 0 citations
Open access Sep 2026

Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma

Remarkable heterogeneity characterizes the resistance mechanisms emerging against osimertinib in EGFR T790M-positive lung adenocarcinoma, with EGFR secondary mutations, bypass signaling pathway activation, and histological transformation representing the primary categories.

Ke-Fan Cui, Ren-Jie Zhu, Jing-Meng Li · 0 citations
Open access Oct 2026

Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.

BACKGROUND Therapeutic strategies after progression on third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) remain suboptimal in EGFR-mutant non-small cell lung cancer (NSCLC). We investigated whether continuing EGFR inhibition with lazertinib combined with platinum-pemetrexed chemotherapy could extend clinical...

M. Hong, B. Shim, C. Kim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.